Pallas Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Pallas Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$732K	Sell	2,212 -1,897	-46%	-$646K	0.03%	404
2025 Q4	$1.63M	Sell	4,109 -316	-7%	-$140K	0.05%	255
2025 Q3	$2.02M	Buy	4,425 +1,855	+72%	+$755K	0.07%	207
2025 Q2	$838K	Sell	2,570 -4,065	-61%	-$1.12M	0.03%	368
2025 Q1	$1.79M	Buy	6,635 +3,227	+95%	+$829K	0.07%	198
2024 Q4	$802K	Buy	3,408 +87	+3%	+$22.9K	0.03%	280
2024 Q3	$975K	Buy	3,321 +1,269	+62%	+$330K	0.04%	228
2024 Q2	$486K	Buy	+2,052	New	+$324K	0.02%	312

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pallas Capital Advisors's ALNY Position: Q1 2026 in Review

Pallas Capital Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 46% in Q1 2026, selling an estimated $646K and leaving 2,212 shares worth $732K. The position accounts for 0.03% of the portfolio, ranked #404.

Pallas Capital Advisors first reported a position in ALNY in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.02M in Q3 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Pallas Capital Advisors held 2,212 shares of Alnylam Pharmaceuticals worth $732K as of Q1 2026.
Pallas Capital Advisors sold 1,897 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $646K.
Alnylam Pharmaceuticals made up 0.03% of Pallas Capital Advisors's portfolio in Q1 2026, its #404 holding.
Pallas Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Pallas Capital Advisors's Alnylam Pharmaceuticals position peaked at $2.02M in Q3 2025.
787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.